CMPI.org
MENU
CMPI
Drugwonks

Reports

The Spreading Cancer of Counterfeit Drugs
October 2020
AARP's Stop Rx Greed Campaign Should Focus on AARP's Rx Greed
January 2020
Restoring the Balance Between Innovation and Generic Manufacturing of Medicines
April 2019
Putting the “Intellectual” Back in “Property”
December 2018
Principles for Patient-Centered Prescription Drug Coverage
September 2017
The Financial Burden of PBM Benefit Design on People Using Specialty Medicines
September 2017
Implications of CRISPR-Based Germline Engineering for Cancer Survivors
August 2017
Commissioner Scott Gottlieb's Predictable Imaginarium
July 2017
Freeing Ourselves from Regulatory Imperialism: A Sanitary Democracy Manifesto
February 2017
Using Off-Label Communications to Responsibly Advance the Public Health
January 2017
The Patient Voice: At the Intersection of a US Regulatory Revolution
August 2016
360 Degree Global Trade Report
May 2016
Of Pens, Pizzas, and Pharmaceuticals
April 2016
Price vs. Value: The story and the rest of the story
September 2015
Pondering PDUFA & Other Policy Drivers
May 2015
openFDA: An Open Question
November 2014
Access to Medical Innovation
September 2014
Biosimilar Nomenclature: Can We Achieve the Truth, the Whole Truth, & Nothing but the Truth?
August 2014
Identifying the Benefits and Risks of Emerging Treatment for Idiopathic Pulmonary Fibrosis: A Qualitative Study
July 2014
Personalized Medicine and Responsible Access to Pain Medication
September 2013
Sign Up for Our Email Newsletter

RECENT NEWS

Waiving COVID-19 Vaccine Patents: A Bad Idea and a Dangerous Precedent

Waiving COVID-19 Vaccine Patents: A Bad Idea and a Dangerous Precedent

Waiving patent protection discourages cutting-edge research investments, which in turn produce breakthrough treatments no...  Read more

'I'm hopeful for the future': Alzheimer's drug approved by FDA

'I'm hopeful for the future': Alzheimer's drug approved by FDA

Peter Pitts of CMPI and Dr. Ronald Petersen of the Mayo Clinic discuss the FDA's approval of aducanumab...  Read more

Biosimilar Strength vs. Potency: Avoiding a Regulatory Hobson’s Choice

Biosimilar Strength vs. Potency: Avoiding a Regulatory Hobson’s Choice

Biosimilars bring lower costs and greater access to the market for biological products, but FDA must determine a predicta...  Read more

Read all News

DRUGWONKS BLOG

RESEARCH ISSUES

Biosimilars
Cure Strategy
Opioids
Personalized Medicine
Price Controls
Safe Drug Use
Tabloid Medicine
The Truth about Drug Pricing
Value of Medical Innovation
Value-Based Reimbursement